Table III.
Comparison of antibiotic resistance profile of extended-spectrum β-lactamases (ESBL)-producing and non-producing Escherichia coli and Klebsiella pneumoniae identified by combined disc test method
| Antibiotics | E. coli | K. pneumoniae | ||
|---|---|---|---|---|
| ESBLs, % (n/N)* | Non-ESBLs, % (n/N) | ESBLs, % (n/N) | Non-ESBLs, % (n/N) | |
| AMK | 5 (8/167) | 12 (75/202) | 57 (56/98) | 43 (54/126) |
| CTX | 59 (99/167) | 61 (123/202) | 87 (85/98) | 57 (72/126) |
| CAZ | 58 (97/167) | 65 (132/202) | 85 (83/98) | 60 (76/126) |
| CIP | 61 (56/92) | 58 (111/191) | 59 (58/98) | 45 (57/126) |
| CFD | 93 (13/14) | 59 (32/54) | 94 (50/53) | 45 (25/56) |
| CHL | 24 (15/62) | 13 (12/90) | 14 (9/64) | 21 (16/76) |
| CFS-SUL | 14 (13/92) | 46 (49/107) | 73 (66/90) | 48 (57/119) |
| CST | 2 (2/88) | 0 | 0 | 7 (8/119) |
| ERT | 34 (10/29) | 48 (29/61) | 21 (11/53) | 43 (27/63) |
| FEP | 55 (92/167) | 64 (129/202) | 85 (83/98) | 57 (72/126) |
| IMP | 4 (7/167) | 34 (69/202) | 44 (43/98) | 48 (60/126) |
| MER | 15 (14/92) | 48 (92/193) | 53 (52/98) | 54 (68/126) |
| TET | 66 (58/88) | 50 (52/103) | 33 (29/89) | 15 (18/119) |
| TZP | 11 (18/167) | 53 (108/202) | 66 (65/98) | 51 (64/126) |
*% (n/N), per cent (number of resistant isolate/total number of isolate). AMK, amikacin; CTX, cefotaxime; CAZ, ceftazidime; FEP, Cefepime; TZP, piperacillin-tazobactam; IMP, imipenem; MER, meropenem, CFS-SUL, cefoperazone-sulbactam, TET, tetracycline; ERT, ertapenem; CIP, ciprofloxacin; CFD, cefpodoxime; CHL, chloramphenicol; CST, colistin